In December 2018, it was announced that SeraCare had been acquired by LGC, an international life sciences measurement and testing company, strengthening LGCâs position in the clinical quality control tools market. Since 1984, SeraCare has provided tools and materials for infectious disease testing in the clinical next-generation sequencing (NGS) market through its oncology, NIPT and inherited disease testing products. In business since 1984, from 2008 SeraCare traded on NASDAQ (SRLS) but in April 2012, the firm was taken private when it was acquired by Linden Capital Partners, a private equity firm. The Company's portfolio has lomgtime included diagnostic controls, plasma-derived reagents and molecular biomarkers, bio banking and contract research services. SearCare operates two segments: Diagnostic and Biopharmaceutical Products, and BioServices. The Diagnostic & Biopharmaceutical Products segment includes two types of products: controls and panels. The Bio Services segment includes bio banking, sample processing and testing services for research and clinical trials, and contract research services in molecular biology, virology, immunology and biochemistry.
